Keytruda Brings New Option To Treatment of PD-L1+ TNBC
The FDA has approved only a few drugs to treat triple-negative breast cancer (TNBC), and last month saw Merck & Co., Inc’s Keytruda (pembrolizumab) gain accelerated approval for the condition. Commercial payers have indicated a willingness to cover it at parity with Roche Group member Genentech USA, Inc.’s Tecentriq (atezolizumab), as well as preferring Keytruda over Tecentriq, but providers are a bit more uncertain about how they will prescribe the newly approved therapy. The condition, though, remains largely unmanaged by payers, a source tells AIS Health.
Some breast cancers test positive for estrogen receptors, progesterone receptors or overexpression of human epidermal growth factor receptor 2 (HER2), but people with TNBC do not have these proteins, which limits their treatment options, according to the American Cancer Society. It also is a fairly aggressive cancer and recurs more often than other breast cancers.
Related Posts

More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends
READ MORE
New FDA Approvals: FDA Gives Accelerated Approval to Mirati’s Krazati
READ MORE